Catalyst Biosciences Inc expected to post a loss of 59  cents a share - Earnings Preview

Gyre Therapeutics

28/02/2022 13:44

* Catalyst Biosciences Inc  CBIO.OQ   CBIO.O  is expected
to show
a fall in quarterly revenue when it reports  results on March 2
(estimated). 
    * The South San Francisco California-based  company is
expected to
report  a 91.8% decrease in revenue to $166.67 thousand from
$2.03 million a year ago, according to the mean estimate from 3
analysts, based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Catalyst
Biosciences Inc
is for a loss of 59 cents per share. For the same quarter last
year, the company reported a loss of 86 cents per share.
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Catalyst
Biosciences Inc is $15​, about 96% above​ its last closing price
of $0.60. ​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2021  -0.67       -0.66      -0.80     Missed  -21.2
 Jun. 30 2021  -0.70       -0.69      -0.64     Beat    7.9
 Mar. 31 2021  -0.57       -0.58      -0.79     Missed  -36.8​
 Dec. 31 2020  -0.95       -0.86      -0.86     Met     0.3
 ​​Sep.        -0.85       -0.81      -0.73     Beat    9.5
 30 2020                                                
 Jun. 30 2020  -0.77       -0.86      -0.96     Missed  -11.3​
 Mar. 31 2020  -0.39       -0.36      -0.28     Beat    23.3
 Dec. 31 2019  0.17        -0.31      -1.13     Missed  -258.7
 This summary was machine generated February 28 at 13:44 GMT. 
All figures in US dollars  unless otherwise stated